Welcome to our dedicated page for Koninklijke Phil SEC filings (Ticker: PHG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Koninklijke Philips N.V. (Royal Philips, NYSE: PHG) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. Philips files annual reports on Form 20-F and interim reports on Form 6-K, which include detailed information on its health technology business spanning diagnostic imaging, ultrasound, image-guided therapy, monitoring, enterprise informatics and personal health.
In its Form 6-K quarterly reports, Philips presents group and segment performance, including comparable order intake growth, comparable sales growth, income from operations, adjusted EBITA margin and free cash flow. The filings break down results for the Diagnosis & Treatment, Connected Care and Personal Health segments, and provide sales by geographic area such as Western Europe, North America, other mature geographies and growth geographies. Management commentary explains how innovation, product mix, productivity measures and tariffs influence margins and cash flow.
These filings also describe innovation highlights and portfolio changes. Examples disclosed in recent 6-Ks and related reports include AI-powered imaging and image-guided therapy solutions, spectral CT and MRI platforms, monitoring partnerships, and productivity programs. Capital allocation topics such as dividend distributions, bond issuance, and productivity targets are discussed, along with notes on ongoing matters like Respironics-related proceedings and insurance income.
Stock Titan enhances access to Philips filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify trends in orders, sales, margins and cash generation. Real-time updates from EDGAR ensure that new Form 6-K submissions and other relevant filings are available as they are published. Users can review historical filings to analyze how segment performance, geographic mix and strategic priorities have evolved over time.
For investors, analysts and healthcare professionals, this page offers a structured view of Philips’ official financial and operational disclosures, supported by AI summaries to make complex SEC filings more approachable.
Koninklijke Philips N.V. reported Q3 2025 results showing continued momentum: comparable order intake grew 8% and group sales were EUR 4.3 billion, up 3.3% on a comparable basis. Income from operations was EUR 330 million. The adjusted EBITA margin rose 50 bps to 12.3% as higher sales, mix and productivity more than offset tariff headwinds.
Operating cash flow was EUR 327 million with free cash flow of EUR 172 million. Segment trends were mixed: Diagnosis & Treatment comparable sales grew 1.3% with margin at 11.8% (down 80 bps), Connected Care grew 5.1% with margin up 410 bps to 11.4%, and Personal Health grew 10.9% with margin at 17.1%.
Philips reiterated its full‑year 2025 outlook: comparable sales growth of 1%–3%, adjusted EBITA margin of 11.3%–11.8% now expected toward the upper end, and free cash flow of EUR 0.2–0.4 billion, which includes the EUR 1,025 million settlements paid in Q1 2025. The outlook excludes ongoing Philips Respironics‑related proceedings.
FAQ
What is the current stock price of Koninklijke Phil (PHG)?
What is the market cap of Koninklijke Phil (PHG)?
